Signant Health Acquires Ametris to Combine Wearable Data and eCOA Technology

Why It Matters

By unifying patient‑reported and sensor‑derived data, the deal cuts operational complexity and strengthens the evidentiary base needed for regulatory approval, accelerating drug development timelines.

Key Takeaways

• Signant Health adds Ametris’s wearable expertise to its eCOA suite
• Integrated platform supports decentralized and hybrid clinical trial models
• Solution targets CNS and complex therapeutic areas needing multimodal data
• AI/ML roadmap aims to create composite outcomes and real‑time monitoring

Pulse Analysis

The convergence of wearable technology and electronic clinical outcome assessments reflects a broader shift toward continuous, real‑world data capture in drug development. Regulators are increasingly demanding richer evidence that blends patient‑reported symptoms with objective physiological signals, especially in complex therapeutic areas such as central nervous system disorders. Companies that can deliver seamless, end‑to‑end data pipelines are gaining a competitive edge, as they reduce the need for multiple point solutions and lower the risk of data silos that can delay trial insights.

Signant Health’s purchase of Ametris addresses this market pressure by integrating two decades of wearable measurement expertise with an established eCOA platform used by over 600 sponsors, including the top 20 pharmaceutical firms. The unified system is built for decentralized and hybrid trial designs, allowing participants to record outcomes from home environments while sponsors retain a single vendor relationship. This consolidation promises faster protocol set‑up, streamlined data validation, and cost efficiencies that are especially valuable as trial budgets tighten and timelines compress.

Looking ahead, the combined entity plans to layer artificial intelligence and machine learning on the merged dataset, targeting the creation of composite outcome measures and real‑time monitoring dashboards. Such capabilities could surface hidden efficacy signals earlier, support adaptive trial designs, and satisfy regulators’ appetite for innovative evidence generation. As the industry leans into digital biomarkers and AI‑enhanced analytics, Signant Health’s strategic move positions it as a pivotal infrastructure provider for the next generation of clinical research.

Deal Summary

Signant Health announced the acquisition of Ametris, a wearable measurement company formerly known as ActiGraph, to integrate eCOA technology with wearable data. Financial terms were undisclosed. The combined platform aims to streamline clinical trial data collection for pharmaceutical sponsors.